The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 Explained: Benefits, Safety & Oral vs Injectable Options FDA Moves to Reevaluate Several Peptides American Med Spa Association Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with